The individualized approach in heart failure with preserved ejection fraction. From clinical practice to Artificial Intelligence

In the last 2 decades heart failure has received a lot of attention; however, little therapeutic progress has been recorded. Globally, more than 60 million people suffer from heart failure, and its prevalence is constantly increasing. Identifying the specific clinical entities and comorbidities associated with different phenotypes of heart failure with preserved ejection fraction may have important clinical implications as it may help guide the development of targeted therapies for these subtypes. Identification and characterization of heart failure phenotypes with preserved ejection fraction is important for guiding diagnosis, management, and research into new treatment strategies.